These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8834412)

  • 1. Paroxetine as a treatment for premenstrual dysphoric disorder.
    Yonkers KA; Gullion C; Williams A; Novak K; Rush AJ
    J Clin Psychopharmacol; 1996 Feb; 16(1):3-8. PubMed ID: 8834412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.
    Sundblad C; Wikander I; Andersch B; Eriksson E
    Eur Neuropsychopharmacol; 1997 Aug; 7(3):201-6. PubMed ID: 9213079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.
    Steiner M; Ravindran AV; LeMelledo JM; Carter D; Huang JO; Anonychuk AM; Simpson SD
    J Clin Psychiatry; 2008 Jun; 69(6):991-8. PubMed ID: 18517289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
    Landén M; Nissbrandt H; Allgulander C; Sörvik K; Ysander C; Eriksson E
    Neuropsychopharmacology; 2007 Jan; 32(1):153-61. PubMed ID: 17035933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Psychiatric and psychological aspects of premenstrual syndrome].
    Limosin F; Ades J
    Encephale; 2001; 27(6):501-8. PubMed ID: 11865558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.
    Wu KY; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):109-14. PubMed ID: 18289149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
    Yonkers KA
    Psychopharmacol Bull; 2003; 37 Suppl 1():135-47. PubMed ID: 14566208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
    Cohen LS; Soares CN; Yonkers KA; Bellew KM; Bridges IM; Steiner M
    Psychosom Med; 2004; 66(5):707-13. PubMed ID: 15385695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group.
    Yonkers KA; Halbreich U; Freeman E; Brown C; Endicott J; Frank E; Parry B; Pearlstein T; Severino S; Stout A; Stone A; Harrison W
    JAMA; 1997 Sep; 278(12):983-8. PubMed ID: 9307345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
    Freeman EW; Rickels K; Sondheimer SJ
    J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
    Pearlstein TB; Stone AB; Lund SA; Scheft H; Zlotnick C; Brown WA
    J Clin Psychopharmacol; 1997 Aug; 17(4):261-6. PubMed ID: 9241004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent, luteal phase nefazodone treatment of premenstrual dysphoric disorder.
    Kodesh A; Katz S; Lerner AG; Finkel B; Sigal M
    J Psychopharmacol; 2001 Mar; 15(1):58-60. PubMed ID: 11277610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria.
    Steinberg S; Annable L; Young SN; Liyanage N
    Biol Psychiatry; 1999 Feb; 45(3):313-20. PubMed ID: 10023508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability.
    Landén M; Erlandsson H; Bengtsson F; Andersch B; Eriksson E
    Neuropsychopharmacology; 2009 Feb; 34(3):585-92. PubMed ID: 18596686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome.
    Eriksson E; Hedberg MA; Andersch B; Sundblad C
    Neuropsychopharmacology; 1995 Apr; 12(2):167-76. PubMed ID: 7779245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial.
    Sundblad C; Modigh K; Andersch B; Eriksson E
    Acta Psychiatr Scand; 1992 Jan; 85(1):39-47. PubMed ID: 1546547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.
    Sundblad C; Hedberg MA; Eriksson E
    Neuropsychopharmacology; 1993 Sep; 9(2):133-45. PubMed ID: 8216696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.